According to data fromS&P Global Market Intelligence, shares of the clinical-stage biotech Juno Therapeutics (NASDAQ: JUNO) gained nearly 12% over the month of February without a discernible catalyst.

Juno Therapeutics has an exclusive license to the St. Jude Children’s Research Hospital patented technology for CD19 directed product candidates that use 4-1BB, which was developed by Dario Campana, ...

SEATTLE--(BUSINESS WIRE)--Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today unveiled its new ...

Seattle-based Juno Theraputics’ shares fell nearly 45 percent Wednesday after the company declared its intent to place a hold on phase two trials of a cancer fighting drug following the death of a ...

GeekWire chronicles the Pacific Northwest startup scene. Sign up for our weekly startup newsletter, and check out the GeekWire funding tracker and VC directory. by Charlotte Schubert on Jan 13, 2022 ...

Kite Pharma Inc. is no longer on the hook for $1.2 billion in damages and royalties a jury awarded to Juno Therapeutics Inc. and the Sloan Kettering Institute for Cancer Research in a patent ...